InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
5
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Alspaugh Jonathan, Chief Financial Officer. Insider active across 1 company, notably Aeglea BioTherapeutics, Inc.. Aggregated, 5 reports have been published. Split: 5 buys · 0 sell. Total volume traded: €575k. History available since 16 August 2021. The latest transaction was filed on 11 March 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations5 total
75,000 shares@ US$2.0824.6% of flowCommon StockSEC:0001209191-22-018941:0
Ideal exit: 6 Dec 2022 (T+270)
50,000 shares@ US$3.7228.5% of flowCommon StockSEC:0001209191-21-069349
Ideal exit: 5 Sept 2022 (T+270)
50,000 shares@ US$3.7228.5% of flowCommon StockSEC:0001209191-21-069349:0
Ideal exit: 5 Sept 2022 (T+270)
9,780 shares@ US$6.36769.2% of flowCommon StockSEC:0001209191-21-052272:0
Ideal exit: 13 May 2022 (T+270)
9,780 shares@ US$6.36769.2% of flowCommon StockSEC:0001209191-21-052272
Ideal exit: 13 May 2022 (T+270)
5 of 5 declarations
About Alspaugh Jonathan
Jonathan Alspaugh is the Chief Financial Officer of Aeglea BioTherapeutics, Inc. He is responsible for the company's financial management, including budgeting and performance analysis. His role is essential in ensuring the financial viability of the organization.
